KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Current Assets (2016 - 2025)

Fulgent Genetics' Current Assets history spans 10 years, with the latest figure at $550.5 million for Q4 2025.

  • For Q4 2025, Current Assets rose 55.69% year-over-year to $550.5 million; the TTM value through Dec 2025 reached $550.5 million, up 55.69%, while the annual FY2025 figure was $550.5 million, 55.69% up from the prior year.
  • Current Assets for Q4 2025 was $550.5 million at Fulgent Genetics, up from $507.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $765.3 million in Q1 2022 and bottomed at $326.5 million in Q3 2024.
  • The 5-year median for Current Assets is $550.2 million (2023), against an average of $538.1 million.
  • The largest annual shift saw Current Assets surged 1680.26% in 2021 before it crashed 40.61% in 2024.
  • A 5-year view of Current Assets shows it stood at $612.0 million in 2021, then increased by 2.6% to $627.9 million in 2022, then decreased by 19.12% to $507.8 million in 2023, then tumbled by 30.38% to $353.6 million in 2024, then soared by 55.69% to $550.5 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Current Assets are $550.5 million (Q4 2025), $507.4 million (Q3 2025), and $428.7 million (Q2 2025).